Lodise Thomas P, Kaye Keith S, Santerre Henriksen Anne, Kahlmeter Gunnar
Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Open Forum Infect Dis. 2024 May 24;11(6):ofae296. doi: 10.1093/ofid/ofae296. eCollection 2024 Jun.
Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing -exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including spp., spp., and spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.
引起尿路感染（UTIs）的尿路病原体中的抗菌药物耐药性在国际上是一个日益严重的问题。匹美西林是美西林的口服前体药物，已使用40多年，主要在北欧和加拿大。在几个国家，它被推荐作为治疗单纯性尿路感染（uUTIs）的一线药物，目前已在美国获得批准。我们进行了一项结构化文献检索，以回顾关于常见引起uUTIs的尿路病原体对美西林敏感性的现有证据。在该文献综述纳入的38项研究中，大多数研究中美西林的敏感率（包括产超广谱β-内酰胺酶等耐药表型）超过90%。在许多其他尿路病原体中也报告了高敏感率，包括 菌属、 菌属和 菌属。在美国当前的处方环境下，匹美西林是uUTI患者可行的一线治疗选择。
